ME Therapeutics to Pitch Next-Gen In-Body Cancer Therapy at Web Summit

VANCOUVER, BC – May 07, 2026 – As the global tech and investment community converges on Vancouver for the highly anticipated Web Summit, a local biotechnology firm is poised to capture the spotlight with a potentially revolutionary approach to fighting cancer. ME Therapeutics Holdings Inc. (CSE: METX), a Vancouver-based company, has secured an exclusive invitation to present at the CSE Capital Tech Connect event on May 13, where CEO Dr. Salim Dhanji will pitch the company's pioneering work in in vivo immune reprogramming to a curated audience of investors.

The presentation, held at the modern downtown hub The Stack, offers a critical platform for the preclinical-stage company. ME Therapeutics is developing therapies designed to reprogram a patient's own immune cells directly inside their body, turning them into potent cancer-fighting agents. This approach aims to sidestep major hurdles facing current cell therapies and could represent the next significant leap in oncology.

The Next Frontier: Reprogramming Immunity Inside the Body

At the heart of ME Therapeutics' strategy is a cutting-edge concept known as in vivo immune reprogramming. This technique seeks to overcome the immense logistical and financial challenges of current Chimeric Antigen Receptor (CAR) T-cell therapies, which have transformed the treatment of some blood cancers but remain complex, expensive, and less effective against solid tumors.

Traditional CAR-T therapy involves a laborious ex vivo process: a patient's T-cells are extracted, genetically engineered in a lab to recognize cancer cells, multiplied, and then re-infused into the patient. In contrast, ME Therapeutics' in vivo approach aims to deliver genetic instructions—specifically mRNA packaged in lipid nanoparticles (LNPs)—directly to immune cells within the body, effectively turning them into CAR cells on-site. This could eliminate the need for cell extraction and external manufacturing, potentially making treatment faster, cheaper, and more accessible.

The company is advancing two primary programs based on this platform. The first is a therapeutic mRNA candidate targeting the STING pathway, an immune signaling route notoriously difficult to drug. In preclinical models of colorectal cancer, this candidate has shown the ability to activate an anti-cancer immune response within the tumor. The second, and perhaps more ambitious, is an in vivo CAR program. Its lead candidate is a dual-targeted CAR aimed at both the CD19 and CD22 proteins found on certain cancer cells, a strategy designed to combat treatment resistance in leukemias and lymphomas.

"It is an honour to be invited by CSE to present our differentiated science, exciting progress to date and investment opportunity,” said Dr. Dhanji in a recent statement. “Activity in the immune reprogramming market continues to accelerate, and ME Therapeutics is at the forefront of this field."

A High-Stakes Pitch on a Global Stage

The invitation to present during Web Summit Vancouver is more than just a speaking engagement; it's a strategic opportunity to connect with the capital needed to fuel the long and arduous journey of drug development. Web Summit Vancouver is a major global conference, attracting over 20,000 entrepreneurs, executives, and, crucially, more than 600 investors from around the world. The CSE Capital Tech Connect event provides a direct conduit to this investment community.

For a preclinical company like ME Therapeutics, which is operating at a loss and has a cash runway of less than a year based on recent financials, securing funding is paramount. The company's success hinges on its ability to persuade investors that its scientific vision can translate into a valuable therapeutic and a sound financial return. The presentation will need to compellingly articulate the potential of its technology to disrupt a CAR-T market projected to exceed $14 billion by 2032, while navigating a highly competitive landscape dominated by pharmaceutical giants like Novartis and Gilead.

Building a Pipeline with Strategic Collaborations

Recognizing the complexity of its mission, ME Therapeutics has pursued a lean and strategic model, augmenting its internal expertise through key partnerships. A cornerstone of its in vivo CAR program is a technology license agreement with the National Research Council of Canada (NRC) for a proprietary nanobody that binds to the CD22 protein. This asset is particularly valuable as CD22 is often present on cancer cells that have relapsed after standard CD19-targeted CAR-T therapy. A therapy utilizing this same NRC nanobody is already being evaluated in a Phase 1 clinical trial for B-cell acute lymphoblastic leukemia, providing important early validation.

To deliver these genetic payloads into the body, ME Therapeutics has partnered with another Vancouver-based innovator, NanoVation Therapeutics. The collaboration gives ME Therapeutics access to NanoVation's advanced LNP delivery technology, which is essential for protecting the mRNA and targeting it to the correct immune cells. This partnership not only accelerates the company's technical capabilities but also provides a vote of confidence, as NanoVation's platform was recently validated through a major partnership with pharmaceutical leader Novo Nordisk.

As Dr. Dhanji prepares to take the stage, the presentation will represent a culmination of these scientific and strategic efforts. He will be pitching not just a company, but a vision for a future where the most advanced cancer therapies are created within the patient's own body, offering a new form of hope in the ongoing fight against the disease.